Somewhat Positive News Coverage Somewhat Unlikely to Affect Evolent Health (NYSE:EVH) Stock Price
Media stories about Evolent Health (NYSE:EVH) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Evolent Health earned a news impact score of 0.10 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 44.5384722883284 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Evolent Health, Inc Class A (NYSE:EVH) Sees Significantly Higher Trading Volume – Modern Readers (modernreaders.com)
- Head-To-Head Contrast: Fluidigm Corporation (FLDM) vs. Evolent Health (EVH) (americanbankingnews.com)
- Evolent Health, Inc Class A (EVH) Stake Increased by Blair William & Co/il – First News 24 (firstnewspaper24.com)
- Evolent Health, Inc. (NYSE:EVH) vs. Mobile Mini, Inc. (NasdaqGS:MINI): How are these stocks valued? – Evergreen Caller (evergreencaller.com)
- Zacks: Analysts Expect Evolent Health, Inc (NYSE:EVH) Will Post Quarterly Sales of $104.54 Million (americanbankingnews.com)
EVH has been the topic of several research reports. Jefferies Group LLC reiterated a “buy” rating and set a $28.00 price target on shares of Evolent Health in a research report on Thursday, April 13th. Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Wednesday, May 3rd. TheStreet upgraded shares of Evolent Health from a “d” rating to a “c-” rating in a research report on Monday, May 22nd. Robert W. Baird initiated coverage on shares of Evolent Health in a research report on Thursday, June 1st. They set an “outperform” rating and a $30.00 price target on the stock. Finally, Leerink Swann reiterated an “outperform” rating and set a $32.00 price target (up previously from $30.00) on shares of Evolent Health in a research report on Monday, June 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $30.10.
Evolent Health (EVH) opened at 24.10 on Monday. Evolent Health has a 52-week low of $14.50 and a 52-week high of $27.50. The firm’s 50-day moving average is $25.82 and its 200-day moving average is $22.62. The firm’s market capitalization is $1.39 billion.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Tuesday, May 9th. The technology company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $104.38 million. During the same period in the previous year, the business posted ($0.16) earnings per share. The business’s revenue for the quarter was up 116.2% compared to the same quarter last year. On average, equities analysts expect that Evolent Health will post ($0.41) earnings per share for the current year.
In other news, Director Cheryl Scott sold 5,477 shares of Evolent Health stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $23.51, for a total transaction of $128,764.27. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total value of $386,799.00. The disclosure for this sale can be found here. Insiders have sold 10,174,238 shares of company stock worth $254,153,952 over the last three months. Insiders own 8.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Evolent Health (NYSE:EVH) Stock Price” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/07/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-evolent-health-nyseevh-stock-price.html.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.